期刊
MEDIATORS OF INFLAMMATION
卷 2016, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2016/6841628
关键词
-
资金
- Bristol-Myers Squib
- Chugai Pharmaceutical Co., Ltd.
- MSD
- Grants-in-Aid for Scientific Research [16K09369] Funding Source: KAKEN
Hepatitis C virus (HCV) infection is a major worldwide health problem. Chronic infection induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual cirrhosis, and possible hepatocellular carcinoma. Eradication of the virus is one of the most important treatment aims. A number of promising new direct-acting antivirals (DAAs) have been developed over the past 10 years. Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs have been approved for patients with HCV, including those with cirrhosis. This review introduces the characteristics and results of recent clinical trials of several DAAs: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors. DAA treatment failure and prognosis after DAA therapy are also discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据